Rilzabrutinib (PRN-1008)
Revision as of 12:51, 6 June 2023 by Warner-admin (talk | contribs) (Text replacement - " (NCT[0-9]{8})" to " https://clinicaltrials.gov/ct2/show/$1")
General information
Class/mechanism: BTK inhibitor
Route: PO
Extravasation: n/a
Preliminary data
Immune thrombocytopenia
- PRN1008-010: Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med. 2022 Apr 14;386(15):1421-1431. link to original article PubMed https://clinicaltrials.gov/ct2/show/NCT03395210
Also known as
- Code name: PRN-1008